Q4 2024 Management View The CEO highlighted that 2024 ended with SUBLOCADE achieving 20% net revenue growth despite challenges, including competition in the U.S. long-acting injectable (LAI) market ...
13h
Key achievements included positive Phase 3 ASPEN data for brensocatib in bronchiectasis, record-breaking ARIKAYCE revenues, and advancements in other pipeline programs such as TPIP and ARIKAYCE's ...
The recall involves "Berry Buddies, Berries & Pancakes" packs that contain undeclared wheat and eggs, posing a risk for those ...
The Trump administration is formally designating eight Latin American crime organizations as “foreign terrorist organizations ...
On January 6, 2025, the US Food and Drug Administration (FDA) published final guidance titled “Communications From Firms to Health Care ...
"Under the updated 'healthy' claim, nutrient-dense foods that are encouraged by the Dietary Guidelines — vegetables, fruits, ...
Explaining America’s weirdly complicated food inspection system, including who regulates poultry and eggs and how Robert F.
On January 6, 2025, the US Food and Drug Administration (FDA) published final guidance titled “Communications From Firms to Health Care ...
Third-quarter results for Medtronic (NYSE:MDT) included a timeline for a planned label expansion for its automated insulin ...
The company said Tuesday it updated the prescribing label of the drug, Librela, to mention rare health problems that had been reported since its introduction in the U.S. in 2023.
Librela (bedinvetmab injection) is a monthly injectable monoclonal antibody, for which real-world drug experience data has been collected in the past year. Zoetis has updated the US label for Librela ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback